Review ArticlesRadiotherapy for Non-Hodgkin LymphomasImber, Brandon S. MD∗; Yahalom, Joachim MD, FACR†Author Information From the ∗Department of Radiation Oncology †Lymphoma Disease Management Team Memorial Sloan Kettering Cancer Center, New York, NY. Conflicts of Interest and Sources of Funding: B.S.I. is supported by the Mortimer J. Lacher, MD fellowship fund. B.S.I. and J.Y. are supported by the Connecticut Cancer Foundation, the Memorial Sloan-Kettering Comedy vs. Cancer grant and the Steven A. Greenberg Award for lymphoma. This work was also supported in part through the National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748. Reprints: Joachim Yahalom, MD, FACR, Lymphoma Disease Management Team, Memorial Sloan Kettering Cancer Center, Koch Building, 530 E 74th St, New York, NY 10021. E-mail: email@example.com. The Cancer Journal: 5/6 2020 - Volume 26 - Issue 3 - p 217-230 doi: 10.1097/PPO.0000000000000453 Buy Metrics Abstract Radiotherapy (RT) plays a diverse and essential role in the contemporary management of non-Hodgkin lymphoma (NHL) and remains the single most powerful monotherapeutic intervention for both aggressive and indolent subtypes. Over the past decade, there have been significant advancements in radiation oncology practice, which have made modern treatments safer and more conformal. Despite this sophistication and evidence supporting a continued role for RT, numerous data suggest that utilization is on the decline. In this review, we discuss the rationale for RT in 4 commonly encountered scenarios: combined modality therapy for limited-stage aggressive NHL, consolidation therapy for advanced-stage aggressive NHL, and the changing roles of salvage RT for relapsed/refractory NHL in an era of new frontiers such as cellular therapies. We also evaluate current strategies to treat indolent histologies. We conclude with perspectives on how RT for the hematological malignancies may continue to evolve. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.